Clinical trial budgets rarely end where they start. Research shows Phase III trials cost an average of $55,716 per day to run in direct operating expenses, but the real damage comes from four structural cost drivers that break budgets during execution. Protocol amendments now affect 76% of trials, up from 57% in 2015, and the mean amendment count per protocol jumped 60% to 3.3. Each amendment takes an average of 260 days to implement fully, during which sites operate under different protocol versions for 215 days. Patient recruitment typically requires nearly double the original timeline, even though nine out of ten trials eventually meet enrollment goals. Site payment negotiations stall when sponsors and sites cannot agree on fair market value, with academic centers taking up to three months and hospital systems up to six months to finalize budgets. Vendor contracts without clear change order triggers turn every operational surprise into a costly renegotiation. The fix starts before the protocol is finalized: investing in design quality, modeling patient populations early, documenting site rate assumptions transparently, and defining scope boundaries tightly in CRO agreements all reduce the avoidable costs that accumulate during trial execution.